Evidence map›Paper›PMID 42856802›Full record

ReviewFrontiers in pharmacology2026

Cannabinoids in hematologic malignancies: mechanisms and therapeutic potential for overcoming drug resistance.

Sixu Li, Xiaokun Jian, Yufu Tang, Zhentao Wang, Tianjiao Min, Luyao Yu, Beier Jiang, Ying He

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sixu Li *College of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
Xiaokun Jian *College of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
Yufu TangNavy Medical Center, Naval Medical University, Shanghai, China.
Zhentao WangNavy Medical Center, Naval Medical University, Shanghai, China.
Tianjiao MinNavy Medical Center, Naval Medical University, Shanghai, China.
Luyao YuNavy Medical Center, Naval Medical University, Shanghai, China.
Beier JiangNavy Medical Center, Naval Medical University, Shanghai, China.
Ying HeNavy Medical Center, Naval Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematologic malignancies are highly heterogeneous diseases in which the emergence of therapy resistance remains a major obstacle to durable clinical benefit. Cannabinoids, acting through the endocannabinoid system, have drawn increasing interest because of their potential to modulate multiple resistance-associated pathways, yet the available evidence remains fragmented across disease entities, experimental models, and mechanistic frameworks. In this narrative review, we examine the molecular mechanisms by which cannabinoids may counteract drug resistance in leukemia, lymphoma, and multiple myeloma. We discuss their effects on ABC transporter-mediated drug efflux, mitochondrial apoptosis, redox homeostasis, endoplasmic reticulum stress and autophagy, pro-survival signaling, and tumor microenvironment-mediated protection. We also evaluate preclinical evidence for cannabinoid-based combinations with conventional chemotherapy, targeted therapies, immunotherapies, and radiotherapy. Although

Indexed as

ABC transporterscannabinoidscombination therapydrug resistancehematologic malignancies

Identifiers

PMID42856802
PMCPMC13650276

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.